NEW YORK–November 11, 2013–(BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) today announced that Robert Bailey was appointed Senior Vice President, Chief Legal Officer General Counsel. In this role, Bailey will be responsible to manage the legal affairs of the Company, and will also serve as the company’s Corporate Secretary. Bailey will report to Brent Saunders, Chief Executive […]
UCLA Researchers Evaluate Long-term Outcomes of More than 1,000 Patients from Multiple Institutions SUNNYVALE, Calif., November 7, 2013 – Accuray Incorporated (Nasdaq: ARAY), announced today the publication of two papers stemming from a large multi-center study of CyberKnife® stereotactic body radiotherapy (SBRT) led by investigators at the University of California, Los Angeles (UCLA). The first […]
Second stage of CLL11 study showed Gazyva plus chlorambucil significantly reduced the risk of disease worsening or death by 61% compared to MabThera/Rituxan plus chlorambucil for people with previously untreated chronic lymphocytic leukemia Updated data from Stage 1a of CLL11 showed Gazyva plus chlorambucil improved overall survival compared to chlorambucil alone Full CLL11 study results […]
NEW YORK–November 7, 2013–(BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories Holdings, Ltd. (collectively, “Forest”) announced today that they have entered into a settlement agreement with Actavis, Inc. and related companies and subsidiaries thereof, in patent infringement litigation brought by Forest in response to Actavis’s abbreviated new drug application (“ANDA”) seeking approval to market generic […]
Data Demonstrate ZFN-dependent CCR5 Modification of Long-lived Central Memory and Stem-like T-cells RICHMOND, Calif., Nov. 4, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of clinical data from its program to develop a ZFP Therapeutic® for HIV/AIDS. The data demonstrate a reduction in the HIV DNA reservoir since receiving SB-728-T in seven of nine HIV-infected subjects […]
SUNNYVALE, Calif., Nov. 4, 2013 (GLOBE NEWSWIRE) — A new study comparing open surgery, video-assisted thoracic surgery (VATS), and robotic-assisted surgery to remove diseased lung tissue found that robotic-assisted surgery is associated with significantly lower death rates, lower overall complication rates, and shorter hospital stays compared with open surgery. Researchers also concluded that robotic-assisted surgery is an […]
Basel, 4 November 2013 – Roche licenses investigational antibiotic POL7080 from Polyphor. POL7080 targets Pseudomonas species with a novel mode of action. This “superbug” bacterium is commonly found in hospitals and has evolved to become resistant to many antibiotic treatments. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Polyphor Ltd., a privately held pharmaceutical company, announced today […]
Gazyva demonstrated an 84 percent reduction in the risk of disease worsening or death when combined with chemotherapy compared to chemotherapy alone Gazyva is the first medicine approved with the FDA’s Breakthrough Therapy Designation Basel, 1 November 2013 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved […]
MINNEAPOLIS and NEW YORK and INDIANAPOLIS, Nov. 1, 2013 /PRNewswire/ — News Highlights: Medtronic and Lilly Diabetes become first ever national presenting sponsors of the #JDRF Walk to Cure #Diabetes Medtronic, Lilly Diabetes help fund more than $500K for #T1D research through #JDRF Walk to Cure #Diabetes national sponsorship Medtronic, Lilly Diabetes’ #JDRF Walk to Cure #Diabetes national sponsorship announcement kicks off #T1Day […]
Basel, Switzerland, October 30, 2013 – Novartis announced today it has filed a Citizen Petition with the US Food and Drug Administration (FDA), urging the Agency to require that a biosimilar share the same INN as the reference product. Novartis files Citizen Petition with FDA, urging uniform approach to use of international nonproprietary names (INN) for […]